The High Sensitivity of the Multi-Cancer Detection Test ONCOVERYX-F Offers a Promising Platform for Ovarian Cancer Screening.
Rajnish NagarkarMamillapalli GopichandSuparna Kanti PalAnkur GuptaNajmuddin Mohd SaquibGanga SagarKanury V S RaoZaved SiddiquiImliwati LongkumerPublished in: International journal of women's health (2024)
We evaluated the potential relevance of our multi-cancer detection test, OncoVeryx-F, for ovarian cancer screening. For this, we compared its accuracy with that of CA125-based screening. We demonstrate here that, in contrast to CA125-based detection, OncoVeryx-F detected ovarian cancer with very high sensitivity and specificity. Importantly here, Stage I cancers too could be detected with an accuracy of >98%. Furthermore, again unlike CA 125, the detection accuracy of OncoVeryx-F remained comparable in both Caucasian and South Asian/Indian women. Thus, the robustness and accuracy of OncoVeryx-F, particularly for early-stage detection, underscores its potential utility for ovarian cancer screening.
Keyphrases
- loop mediated isothermal amplification
- early stage
- real time pcr
- label free
- papillary thyroid
- magnetic resonance
- magnetic resonance imaging
- squamous cell carcinoma
- type diabetes
- metabolic syndrome
- adipose tissue
- climate change
- radiation therapy
- risk assessment
- polycystic ovary syndrome
- computed tomography
- lymph node
- protein kinase
- single cell
- childhood cancer
- insulin resistance
- human health